Xencor Shares Climb 23.94% on XmAb819 Kidney Cancer Results
Photo: TokenPost
Xencor shares rose 23.94% Monday, Oct. 26, after results from a Phase 1 trial of XmAb819 showed a 45.5% response rate in advanced kidney cancer. XmAb819 is a drug studied for advanced kidney cancer. Xencor plans accelerated discussions with the Food and Drug Administration (FDA). The broader U.S. market backdrop was mixed: futures steadied Monday morning after two consecutive weekly declines in major indexes. Oil prices remained elevated, and skepticism over AI capital spending persisted. Enna Lee reports on investing and digital-asset markets for TokenPost. Send corrections or tips to info@tokenpost.com.
Source: TokenPost
